Beam Therapeutics (BEAM) closed at $27.23 on October 30, 2026, down 5.6% from the previous close, on volume of 1,413,549 shares (30-day average 1,775,146).
Data as of October 30, 2026.
FDA draft guidance aims to speed personalized gene therapies for rare diseases
Seeking Alpha News (Thu, 29-Oct 3:52 PM ET)
Analysts Are Bullish on Top Healthcare Stocks: Icon (ICLR), Beam Therapeutics (BEAM)
TipRanks (Wed, 28-Oct 11:41 AM ET)
UBS Sticks to Their Hold Rating for Beam Therapeutics (BEAM)
TipRanks (Wed, 28-Oct 8:46 AM ET)
Beam Therapeutics (BEAM) Gets a Buy from Citi
TipRanks (Tue, 27-Oct 9:35 PM ET)
TipRanks (Tue, 27-Oct 9:31 PM ET)
Globe Newswire (Tue, 27-Oct 7:00 AM ET)
PRNewswire (Thu, 15-Oct 10:02 AM ET)
Globe Newswire (Tue, 13-Oct 7:00 AM ET)
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
Business Wire (Wed, 16-Sep 7:46 PM ET)
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Beam Therapeutics trades on the NASDAQ stock market under the symbol BEAM.
As of October 30, 2026, BEAM stock price declined to $27.23 with 1,413,549 million shares trading.
BEAM has a beta of 2.58, meaning it tends to be more sensitive to market movements. BEAM has a correlation of 0.25 to the broad based SPY ETF.
BEAM has a market cap of $2.80 billion. This is considered a Mid Cap stock.
Last quarter Beam Therapeutics reported $490,000 in Revenue and -$1.18 earnings per share. This fell short of revenue expectation by $-18 million and missed earnings estimates by -$.07.
In the last 3 years, BEAM traded as high as $49.50 and as low as $13.53.
The top ETF exchange traded funds that BEAM belongs to (by Net Assets): ARKE, ARKK, XBI, ARKG, VTI.
BEAM has underperformed the market in the last year with a return of +9.9%, while SPY returned +11.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BEAM shares. However, BEAM has outperformed the market in the last 3 month and 2 week periods, returning +4.7% and +10.1%, while SPY returned +3.9% and -2.1%, respectively. This indicates BEAM has been having a stronger performance recently.
BEAM support price is $27.66 and resistance is $30.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BEAM shares will trade within this expected range on the day.
